ArticleBMC gastroenterology2026
Effectiveness and safety of tenofovir amibufenamide in the treatment of chronic hepatitis B patients with low-level viremia: a retrospective real-world study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTenofovir amibufenamide (TMF) and tenofovir alafenamide (TAF) are considered efficacious and safe nucleoside/nucleotide analogs (NAs) for patients with chronic hepatitis B (CHB). However, real-world data on TMF for CHB patients with low-level viremia (LLV) remain scarce. This study investigated the real-world effectiveness and safety of TMF combined with entecavir (ETV) in the treatment of CHB patients with LLV, and compared the efficacy and safety of TMF combined with ETV and tenofovir alafenamide (TAF) combined with ETV in the treatment of CHB patients with LLV.
methodsThis retrospective real-world study included CHB patients with LLV who received treatment with either TMF combined with ETV or TAF combined with ETV. After the 48-week follow-up, this study evaluated the differences between the two groups in terms of virological response rate (VR rate), ALT normalization rate, HBsAg and HBeAg seroclearance rate, liver fibrosis assessment, and safety endpoints (renal function and blood lipids).
resultsA total of 258 patients were enrolled: 123 in the experimental group (TMF combined with ETV) and 135 in the control group (TAF combined with ETV). The levels of HBV DNA and AST in both groups were significantly lower than the baseline levels after 48-week treatment period (P < 0.05). The VR rate at week 48 was 79.67% in the experimental group, while that in the control group was 72.59%, and there was no statistically significant difference between the two groups (P = 0.184). With respect to the ALT normalization rate, HBsAg seroclearance rate, HBeAg seroclearance rate and liver transient elastography (TE) results, no statistically significant differences were detected between the two groups (P > 0.05). Similarly, for the safety endpoints, including serum creatinine (Cr), glomerular filtration rate (eGFR), triglyceride (TG), total cholesterol (TC), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) levels, none of these indicators significantly differed between the two groups.
conclusionTMF combined with ETV was found to be effective in CHB patients with LLV and appeared to have a favorable safety profile within the limitations of the available data. It exhibits robust antiviral activity and can improve the liver function of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.